Clinical trial
A Multiple Ascending Dose Study of R1530 in Patients With Advanced Solid Tumors.
NCT00493155 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00493155 |
|---|---|
| Title | A Multiple Ascending Dose Study of R1530 in Patients With Advanced Solid Tumors. |
| Official title | "An Open-label, Multiple Ascending Dose Study to Determine the Maximum Tolerated Dose of R1530 in Patients With Advanced Solid Tumors." |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasms |
| Intervention type | Drug |
| Interventions | RG1530 |
| Enrollment | 48 |
| Start date | Oct 1, 2005 |
| Primary completion | Feb 1, 2009 |
| Completion | Feb 1, 2009 |
| First posted | Jun 28, 2007 |
| Last update posted | Nov 2, 2016 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: